(WAYNE, N.J.) -- Following two studies that claim hormones used in newer birth control pills could put women at a greater risk of developing blood clots, Bayer HealthCare Pharmaceuticals, Inc. -- who had three drugs put into question -- has come out with its response.
In a statement released Thursday after the studies were published, the pharmaceutical company said it "re-affirms that the overall body of available scientific evidence continues to provide support that the risk of developing venous thromboembolism, or blood clots, in women using drospirenone-containing combination oral contraceptives is comparable to other combination birth control pills studied."
The studies found that women who take drospirenone-containing pills, like Bayer's Yazmine, Yaz and Ocella, had a two-to-three-fold increased risk of developing clots compared to levonorgestrel-containing pills.
Bayer contended "that the manner in which the authors applied the study methodology reported in these two publications and the databases used provide less reliable conclusions than are available from existing scientific evidence."
The company also said the findings "do not change the overall assessment about the safety of Bayer's oral contraceptives."
Copyright 2011 ABC News Radio